Ryanodex (Dantrolene Sodium)
Brand Names: Ryanodex
Methodology & AI Transparency ⓘ
Ryanodex (Dantrolene Sodium) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Marketed under the trade name Ryanodex (registered by Eagle Pharmaceuticals, Inc., RxNorm 856656-B42367540), this prescription brand-name formulation contains Dantrolene Sodium within the Skeletal Muscle Relaxant therapeutic class.
- 2 Real-world patient consensus: Branded skeletal muscle relaxant presentation of Dantrolene Sodium (Eagle Pharmaceuticals, Inc.); generic reference: /meds/dantrolene-sodium.
- 3 Typical cash cost range: Public pharmacy ledger: $64.46 low cash benchmark vs. $170.82 chain retail average ($0.7773/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Ryanodex (Dantrolene Sodium)): dizziness (9%), diarrhea (8.4%), fatigue (8.8%).
Ask our AI Specialists anything about Ryanodex (Dantrolene Sodium)
Ryanodex (Dantrolene Sodium) Mechanism, CYP450 Pathways & DailyMed Monograph
Marketed under the trade name Ryanodex (registered by Eagle Pharmaceuticals, Inc., RxNorm 856656-B42367540), this prescription brand-name formulation contains Dantrolene Sodium within the Skeletal Muscle Relaxant therapeutic class. Per 2024-10-29 DailyMed labeling (42367-540), clinical use centers on 250 mg/5mL Injection, Suspension; 25mg Capsule: In Chronic Spasticity Dantrolene sodium capsules are indicated in controlling the manifestations of clinical spasticity.
At the receptor and enzymatic level, Ryanodex delivers Dantrolene Sodium to execute skeletal muscle relaxant modulation with class-characteristic hepatorenal disposition. Specific to the Ryanodex commercial product (NDC 42367-540, RxCUI 856656-B42367540), tablet/vehicle compounding registered by Eagle Pharmaceuticals, Inc. standardizes delivery across 250 mg/5mL Injection, Suspension; 25mg Capsule, contrasting $64.46 discount cash access against $170.82 walk-in retail pricing.
Following administration (250 mg/5mL Injection, Suspension), Ryanodex (Dantrolene Sodium) achieves Complete (~100%) parenteral systemic delivery for Ryanodex (Dantrolene Sodium) (250 mg/5mL Injection, Suspension) bioavailability and rapid intravascular/parenteral onset within 15–45 minutes after ryanodex (dantrolene sodium) administration onset, governed by a Steady-state plasma equilibrium reached over 6–14 hour t½ intervals for Ryanodex (Dantrolene Sodium) terminal half-life through predominantly hepatic biotransformation with renal elimination of polar ryanodex (dantrolene sodium) conjugates.
Before initiating Ryanodex (Dantrolene Sodium) at 250 mg/5mL Injection, Suspension, clinical safety checklists rule out confirmed ige-mediated allergy or cutaneous reaction to ryanodex (dantrolene sodium) (dantrolene sodium) components; uncompensated hepatic or renal insufficiency incompatible with ryanodex (dantrolene sodium) (250 mg/5ml injection, suspension) clearance. Logged tolerability patterns center on dizziness (9% of reports), fatigue (8.8% of reports), diarrhea (8.4% of reports).
Reconcile eGFR-adjusted medications before escalating Ryanodex (Dantrolene Sodium) in polypharmacy regimens.
Botanical enzyme modulators may alter oral first-pass exposure of Ryanodex (Dantrolene Sodium); disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Ryanodex (Dantrolene Sodium) (Dantrolene Sodium) components
- Uncompensated hepatic or renal insufficiency incompatible with Ryanodex (Dantrolene Sodium) (250 mg/5mL Injection, Suspension) clearance
Logged Side-Effect Incidence (8 Reports)
Ryanodex (Dantrolene Sodium) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Ryanodex (Dantrolene Sodium))
Human clinical trial evidence for Ryanodex (Dantrolene Sodium) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Ryanodex (Dantrolene Sodium) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.7773/unit (~$23.32/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $170.82 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 8 Anonymous DotMD Community Micro-Logs | $64.46 / mo | View logs ↓ |
Ryanodex (Dantrolene Sodium) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Ryanodex (Dantrolene Sodium) RxNorm Concept ID | 856656-B42367540 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.7773 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $170.82 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $64.46 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (8 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Ryanodex (Dantrolene Sodium) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Ryanodex (Dantrolene Sodium): FDA labeling (2024-10-29, NDC 42367-540), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Ryanodex (Dantrolene Sodium) community threads and patient logs by age, biological sex, dosage, and treatment duration.